31722-044 : Zileuton 600 mg Oral Tablet, Film Coated, Extended Release


NDC31722-044
Labeler: Camber Pharmaceuticals, Inc.
Product Type: Human Prescription Drug
Drug Name:  Zileuton
Dosage Form: Oral Tablet, Film Coated, Extended Release
Application #: ANDA215742
Rev. Date: 


NDC Package Codes:

  • 31722-044-12: 120 TABLET, FILM COATED, EXTENDED RELEASE IN 1 BOTTLE (31722‑044‑12)

Active Ingredients:

  • Zileuton

Dosage Strength:

  • 600 mg

Pharmaceutical Classes:

  • 5-Lipoxygenase Inhibitor [EPC]
  • 5-Lipoxygenase Inhibitors [MoA]
  • Decreased Leukotriene Production [PE]

Related Products:

Based on records with the same trade name.
  • 24486-902 Zileuton 600 mg Oral Tablet, Extended Release by Aristos Phamaceuticals, Inc.
  • 49884-723 Zileuton 600 mg Oral Tablet, Multilayer, Extended Release by Par Pharmaceutical, Inc.
  • 51407-741 Zileuton 600 mg Oral Tablet, Multilayer, Extended Release by Golden State Medical Supply, Inc.
  • 64380-189 Zileuton 600 mg Oral Tablet, Multilayer, Extended Release by Strides Pharma Science Limited
  • 64980-206 Zileuton 600 mg Oral Tablet, Extended Release by Rising Pharmaceuticals, Inc.
  • 66993-485 Zileuton 600 mg Oral Tablet, Extended Release by Prasco, LLC
  • 68180-169 Zileuton 600 1/1 Oral Tablet, Extended Release by Lupin Pharmaceuticals, Inc.
  • 69339-130 Zileuton 600 mg Oral Tablet, Multilayer, Extended Release by Dash Pharmaceutical LLC
  • 72603-246 Zileuton 600 mg Oral Tablet, Film Coated, Extended Release by Northstar Rxllc

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 31722-044 QR Code

< Prev: 31722-043Next: 31722-045 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.